Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, and shares rose, reversing a premarket dive.
We are experiencing some temporary issues. The market data on this page is currently delayed.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal ·
Investor's Business Daily
